FITC Anti-Mouse CD272/BTLA Antibody[PJ196]

B and T lymphocyte attenuator (BTLA) is an Ig superfamily coinhibitory receptor with structural similarity to programmed cell death 1 (PD-1) and CTLA-4. BTLA is expressed on B cells, T cells, macrophages, dendritic cells, NKT cells, and NK cells. Engagement of BTLA by its ligand Herpes Virus Entry Mediator (HVEM) is critical for negatively regulating immune response. The absence of BTLA with HVEM inhibitory interactions leads to increased experimental autoimmune encephalomyelitis severity, enhanced rejection of partially mismatched allografts, an increased CD8+ memory T cell population, increased severity of colitis, and reduced effectiveness of T regulatory cells. BTLA plays an important role in the induction of peripheral tolerance of both CD4+ and CD8+ T cells in vivo. Tolerant T cells have significant up-regulated expression of BTLA compared with effector and na?ve T cells. BTLA may cooperate with CTLA-4 and PD-1 to control T cell tolerance and autoimmunity. It has been reported that BTLA may regulate T cell function through binding to B7-H4.

Phosphate buffered solution, pH 7.2, containing 0.09% stabilizer.

5 uL/Test

FITC

24 months

151888

BTLA, B and T lymphocyte attenuator

Q7Z6A9

Each lot of this antibody is quality control tested by flow cytometric analysis. The amount of the reagent is suggested to be used 5 uL of antibody per test (million cells in 100 uL staining volume or per 100 uL of whole blood). Please check your vial before the experiment. Since applications vary, the appropriate dilutions must be determined for individual use.